[go: up one dir, main page]

AR123672A2 - Conjugados de anticuerpo fármaco - Google Patents

Conjugados de anticuerpo fármaco

Info

Publication number
AR123672A2
AR123672A2 ARP200100581A ARP200100581A AR123672A2 AR 123672 A2 AR123672 A2 AR 123672A2 AR P200100581 A ARP200100581 A AR P200100581A AR P200100581 A ARP200100581 A AR P200100581A AR 123672 A2 AR123672 A2 AR 123672A2
Authority
AR
Argentina
Prior art keywords
alkynyl
alkenyl
alkyl
coora
cora
Prior art date
Application number
ARP200100581A
Other languages
English (en)
Inventor
Garca-Ibarrola Mara Garranzo
Solloso Andrs Francesch
Correa Juan Manuel Domnguez
Alonso Mara Jos Muoz
Madrid Francisco Snchez
Hernandez Juan Manuel Zapata
Arroyo Alicia Garca
Pecharromn Mara Angeles Ursa
Marchante Mara Del Carmen Cuevas
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of AR123672A2 publication Critical patent/AR123672A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Conjugados de fármaco de fórmula [D-(X)ᵇ-(AA)ʷ-(L)-]ₙ-Ab en la que: D es un resto de fármaco que tiene la siguiente fórmula (1) o una sal, éster, solvato, tautómero o estereoisómero aceptable desde el punto de vista farmacéutico, en la que: A se selecciona de los compuestos de fórmula (2) y (3); R¹, R² y R³ es H, ORᵃ, OCORᵃ, OCOORᵃ, alquilo, alquenilo, alquinilo, etc.; R³’ es, CORᵃ, COORᵃ, CONRᵃRᵇ, etc.; cada uno de R⁴ a R¹⁰ y R¹² es alquilo, alquenilo, o alquinilo; R¹¹ es H, CORᵃ, COORᵃ, alquilo, alquenilo o alquinilo, o R¹¹ y R¹² + N + C átomos a los cuales se unen pueden formar un grupo heterocíclico; cada uno de R¹³ y R¹⁴ es H, CORᵃ, COORᵃ, alquilo, alquenilo o alquinilo; cada uno de Rᵃ y Rᵇ es H, alquilo, alquenilo, alquinilo, etc.; cada línea punteada representa un enlace adicional opcional; X es un grupo extensor; AA es una unidad de aminoácido; L es un grupo conector; w es 0 a 12; b es 0 ó 1; Ab es un resto que comprende al menos un sitio de unión al antígeno, y n es la relación del grupo [D-(X)ᵇ-(AA)ʷ-(L)-] al resto que comprende al menos un sitio de unión al antígeno y está en el intervalo de 1 a 20, son útiles en el tratamiento de cáncer.
ARP200100581A 2013-05-31 2020-03-03 Conjugados de anticuerpo fármaco AR123672A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1309807.4A GB201309807D0 (en) 2013-05-31 2013-05-31 Antibody drug conjugates

Publications (1)

Publication Number Publication Date
AR123672A2 true AR123672A2 (es) 2023-01-04

Family

ID=48805601

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140102164A AR096461A1 (es) 2013-05-31 2014-06-03 Anticuerpos conjugados de fármacos
ARP200100581A AR123672A2 (es) 2013-05-31 2020-03-03 Conjugados de anticuerpo fármaco

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140102164A AR096461A1 (es) 2013-05-31 2014-06-03 Anticuerpos conjugados de fármacos

Country Status (30)

Country Link
US (2) US11224663B2 (es)
EP (1) EP3003386B1 (es)
JP (1) JP6412114B2 (es)
KR (2) KR102448393B1 (es)
CN (1) CN105451775B (es)
AR (2) AR096461A1 (es)
AU (1) AU2014273052B2 (es)
BR (1) BR112015029816B1 (es)
CA (1) CA2914041C (es)
CL (1) CL2015003481A1 (es)
CY (1) CY1122662T1 (es)
DK (1) DK3003386T3 (es)
ES (1) ES2778045T3 (es)
GB (1) GB201309807D0 (es)
HR (1) HRP20200032T1 (es)
IL (1) IL242571B (es)
LT (1) LT3003386T (es)
MX (1) MX356431B (es)
MY (1) MY176579A (es)
NZ (1) NZ715646A (es)
PL (1) PL3003386T3 (es)
PT (1) PT3003386T (es)
RS (1) RS59855B1 (es)
RU (1) RU2669812C2 (es)
SG (1) SG11201509563UA (es)
SI (1) SI3003386T1 (es)
SM (1) SMT202000023T1 (es)
UA (1) UA119327C2 (es)
WO (1) WO2014191578A1 (es)
ZA (1) ZA201508487B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170058043A1 (en) * 2014-12-06 2017-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
CN108025035B (zh) * 2015-08-03 2023-06-13 Enb治疗公司 用于治疗与etbr激活相关的癌症的组合物和方法
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
WO2018075308A1 (en) * 2016-10-17 2018-04-26 Princeton Enduring Biotech, Inc. Long acting multi-specific molecules and related methods
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US11612666B2 (en) * 2017-11-30 2023-03-28 Seagen Inc. Process for the preparation of drug linker compounds
CA3081559A1 (en) * 2017-12-01 2019-06-06 Abbvie Inc. Anti-cd40 antibody drug conjugates
CA3086926A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
EP3866853A4 (en) * 2018-10-21 2022-08-03 SLSG Limited LLC MULTI-IMMUNOTHERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
MA53765B2 (fr) 2018-12-21 2025-04-30 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués tubulysines-protéines
EP3964236A4 (en) * 2019-05-02 2023-05-31 LegoChem Biosciences, Inc. LIGAND-DRUG CONJUGATE COMPRISING A LINKER HAVING A TRIS STRUCTURE
WO2020222573A1 (ko) * 2019-05-02 2020-11-05 주식회사 레고켐 바이오사이언스 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
CN119770674A (zh) * 2019-05-10 2025-04-08 武田药品工业株式会社 抗体药物缀合物
RU2745738C1 (ru) * 2019-05-20 2021-03-31 МэбПлекс Интернэшнл Ко., Лтд. Однореакторный способ получения промежуточного продукта конъюгата антитело-лекарственное средство
LT3833657T (lt) * 2019-07-31 2022-10-10 Advanced Biodesign Aminotiolesterų junginiai ir jų naudojimas
JP2023522259A (ja) * 2020-04-21 2023-05-29 ファルマ、マール、ソシエダード、アノニマ 薬物抗体コンジュゲート
CN114262377B (zh) * 2021-10-28 2024-03-22 新疆优迈生物技术有限公司 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列
CN115873066A (zh) * 2022-07-27 2023-03-31 吉林省博大伟业制药有限公司 一种抗体偶联药物连接子的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
DK1594542T3 (da) * 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
SG174830A1 (en) * 2006-06-16 2011-10-28 Pharma Mar Sa Antitumoral dihydropyran-2-one compounds
WO2009080761A1 (en) 2007-12-20 2009-07-02 Pharma Mar, S.A. Antitumoral compounds
AU2009248997A1 (en) 2008-05-23 2009-11-26 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors
US8900589B2 (en) 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
AR096461A1 (es) 2015-12-30
LT3003386T (lt) 2020-01-27
CA2914041C (en) 2021-12-07
KR20160030132A (ko) 2016-03-16
CL2015003481A1 (es) 2016-08-19
AU2014273052B2 (en) 2018-03-08
KR102340681B1 (ko) 2021-12-20
US11224663B2 (en) 2022-01-18
KR20210156848A (ko) 2021-12-27
PT3003386T (pt) 2020-01-21
AU2014273052A1 (en) 2016-01-28
ES2778045T3 (es) 2020-08-07
UA119327C2 (uk) 2019-06-10
RU2015156499A3 (es) 2018-03-27
US20220168436A1 (en) 2022-06-02
KR102448393B1 (ko) 2022-09-28
EP3003386B1 (en) 2019-10-16
JP2016526042A (ja) 2016-09-01
CN105451775A (zh) 2016-03-30
RS59855B1 (sr) 2020-02-28
HRP20200032T1 (hr) 2020-03-20
JP6412114B2 (ja) 2018-10-24
MX2015016417A (es) 2016-07-05
SG11201509563UA (en) 2015-12-30
US20160129128A1 (en) 2016-05-12
BR112015029816A2 (pt) 2017-07-25
PL3003386T3 (pl) 2020-04-30
EP3003386A1 (en) 2016-04-13
DK3003386T3 (da) 2020-01-27
SI3003386T1 (sl) 2020-03-31
IL242571B (en) 2019-10-31
RU2015156499A (ru) 2017-06-30
RU2669812C2 (ru) 2018-10-16
CA2914041A1 (en) 2014-12-04
MX356431B (es) 2018-05-29
NZ715646A (en) 2019-05-31
SMT202000023T1 (it) 2020-03-13
BR112015029816B1 (pt) 2022-10-04
US12410148B2 (en) 2025-09-09
MY176579A (en) 2020-08-17
GB201309807D0 (en) 2013-07-17
ZA201508487B (en) 2017-11-29
CN105451775B (zh) 2019-09-06
WO2014191578A1 (en) 2014-12-04
CY1122662T1 (el) 2021-03-12

Similar Documents

Publication Publication Date Title
AR123672A2 (es) Conjugados de anticuerpo fármaco
AR121016A2 (es) Sales de fenotiazindiaminio y su uso
MA38647B1 (fr) Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x
IL281247A (en) Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
AR100006A1 (es) Derivados de tubulisina
BR112017012755A2 (pt) compostos de heteroarila de anel fundido e seu uso como inibidores de trk
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EP4117729A4 (en) ANTIBODY-DRUG CONJUGATE
CY1120104T1 (el) Αναστολεις της syk
SA521421855B1 (ar) مترافقات عقار-جسم مضاد
CY1119677T1 (el) Παραγωγα δολαστατινης 10 και αουριστατινων
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
AR094959A1 (es) Compuestos de imidazo piridina
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
AR117229A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
EP4221690A4 (en) PHARMACEUTICAL COMPOSITIONS
IL283313A (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
CY1124967T1 (el) Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2
MA54521A (fr) Dérivés d'oxopyridine substitués
EP4135699A4 (en) Pharmaceutical compositions
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
AR094100A1 (es) DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib